Pfizer (PFE) announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A without FVIII inhibitors or severe hemophilia B without FIX inhibitors. Hympavzi is the first and only anti-tissue factor pathway inhibitor approved in the European Union, or EU, for the treatment of hemophilia A or B and the first hemophilia medicine approved in the EU to be administered via a pre-filled, auto-injector pen. HYMPAVZI offers a subcutaneous treatment option with a once-weekly dosing schedule and minimal preparation required for each individual administration.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE:
- Arvinas initiated with an Overweight at Stephens
- Moderna (MRNA) and Other Vaccine Stocks Fall on News of RFK Jr. Health Nomination
- New York Times files lawsuit against EC over Covid vaccine deal, NY Times says
- Wolfe starts Pfizer at Underperform, notes underperformance versus peers
- Vaccine makers fall after Trump nominates RFK to head HHS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
